NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









GIVAX

GIVAX

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.givax.bio/

Last Round

Seed

Apr 6, 2022

Total Funding Raised

$12M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

GIVAX is a biotechnology company developing a novel oral vaccine platform designed to eliminate the burden of preventable GI disease in children and adults.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

oral vaccine platformrotavirus vaccinenorovirus vaccinemucosal immunityrotavirus vectorviral vector platformneedle-free vaccinecombination vaccinesgastrointestinal diseasesGI diseasesstomach flu vaccineoral deliverypediatric vaccinevaccine developmentbiopharma partnershipsvaccine licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GIVAX Comparables

Compare GIVAX with similar companies based on industry and business-model similarity.

GIVAX comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vaxart, Inc.
72%
Esperovax
72%
VLP Therapeutics
71%
View all Comparables

GIVAX Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 6, 2022
View all Funding Rounds

Key People

Founding team and executive leadership

Mario Barro

CEO President GIVAX

Executive Team

GIVAX Investors

Notable investors and investment history

GIVAX investors
InvestorRounds
RA Capital ManagementSeed
Kurma PartnersSeed
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors increased 274% MoM.

  • Jun 8, 2026

    Grew 20% QoQ from 15 to 18 employees.

View all signals

GIVAX Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GIVAX Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GIVAX's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range18
Year Founded2021
Last FundingApr 6, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.